Vanguard Global Advisers
OKUR

Vanguard Global Advisers’s OnKure Therapeutics OKUR Stock Holding History

Vanguard Global Advisers’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-745
Closed -$3.08K – 3752
2026
Q1 		$3.08K Buy
+745
New +$2.3K ﹤0.01% 3593

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Global Advisers's OKUR Position: Q2 2026 in Review

Vanguard Global Advisers sold out of OnKure Therapeutics (OKUR) in Q2 2026, closing a stake of 745 shares — an estimated $3.08K sold.

Vanguard Global Advisers first reported a position in OKUR in Q1 2026 and held it in 1 quarter. The position peaked at $3.08K in Q1 2026. 67 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Vanguard Global Advisers reported no remaining OnKure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 745 OnKure Therapeutics shares in Q2 2026, an estimated $3.08K.
  • Vanguard Global Advisers first reported a position in OnKure Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's OnKure Therapeutics position peaked at $3.08K in Q1 2026.
  • 67 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.